Cargando…

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

OBJECTIVES: The treatments for high-grade non-muscle invasive bladder cancer (NMIBC) vary between bladder preserving intravesical approaches and radical cystectomy. The impact of these treatments on health-related quality of life may vary widely. The purpose of this study was to elicit the general p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Owen Alan Edwards, Ghatnekar, Ola, Piglowska, Natalia, Smith, Charlie A., Swinburn, Paul, Catto, James W. F., Niegisch, Günter, Jakobsen, Jørn Skibsted
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897878/ https://www.ncbi.nlm.nih.gov/pubmed/36737511 http://dx.doi.org/10.1007/s41669-023-00392-4

Ejemplares similares

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951)

Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018)

Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency
por: Al-Hammadi, Suleiman, et al.
Publicado: (2017)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG)
por: Steinberg, Gary, et al.
Publicado: (2015)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Li, Roger, et al.
Publicado: (2017)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage
por: Nikas, Christine V., et al.
Publicado: (2020)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)
por: Steinberg, Gary D, et al.
Publicado: (2014)

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
por: Deininger, Susanne, et al.
Publicado: (2022)

Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy
por: Afonso, Raquel, et al.
Publicado: (2022)

Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
por: Farah, Naim B, et al.
Publicado: (2014)

Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance
por: Cernuschi, Tania, et al.
Publicado: (2018)

Microbic Dissociation; with Reference to the Attenuated Tubercle Bacillus of Calmette and Guerin (B.C.G.)
por: Begbie, R. S.
Publicado: (1931)

Henoch Schönlein Purpura Nephritis Associated with Intravesical Bacillus Calmette-Guerin (BCG) Therapy
por: Tsukada, Hiroyuki, et al.
Publicado: (2017)

The Bacillus Calmette-Guérin (BCG) Vaccine: Is it a better choice for the treatment of viral warts?
por: Al-Yassen, Asaad Q., et al.
Publicado: (2020)

Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
por: Mahasha, Phetole Walter, et al.
Publicado: (2019)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
por: Kawai, Akihito, et al.
Publicado: (2022)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
por: Suh, Jungyo, et al.
Publicado: (2021)

Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation: A case report
por: Moussa, M., et al.
Publicado: (2018)

Systemic Bacillus Calmette-Guérin (BCG) Infection and Accompanying Warm Autoimmune Haemolytic Anaemia Following Intravesical BCG Immunotherapy
por: Güven, Alper Tuna, et al.
Publicado: (2023)

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.
por: Pryor, K., et al.
Publicado: (1995)

Poncet’s disease after the intravesical instillation of Bacillus Calmette–Guérin (BCG): a case report
por: Sampaio, Paula Cíntia Machado, et al.
Publicado: (2017)

Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19
por: Berg, Martha K., et al.
Publicado: (2020)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer’s disease in bladder cancer patients
por: Gofrit, Ofer N., et al.
Publicado: (2019)

Case Reports of Bacillus Calmette-Guérin (BCG) Osteomyelitis: A Rare Complication in Immunocompetent Infants
por: Ghoweba, Yousra, et al.
Publicado: (2020)

Re: The Bacillus Calmette-Guerin (BCG) Vaccine: Is it a better choice for the treatment of viral warts?
por: Al-Mendalawi, Mahmood D.
Publicado: (2021)

Expanded Scope of Bacillus Calmette-Guerin (BCG) Vaccine Applicability in Disease Prophylaxis, Diagnostics, and Immunotherapeutics
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2020)

Bacillus of Calmette and Guérin (BCG) and the risk of leprosy in Ciudad del Este, Paraguay, 2016–2017
por: Cuevas, Nancy Carolina, et al.
Publicado: (2021)

Immunotherapy With Bacillus Calmette-Guerin (BCG) in a 16-Year-Old With Urothelial Bladder Carcinoma
por: Martinez-Thomas, Jose M, et al.
Publicado: (2022)

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)
por: Witjes, J Alfred, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a88qboojha9k0un7hadh722o4b